Stocks to Watch: Intel, PTC Therapeutics, KLA
By Sabela Ojea
Intel on Thursday delivered a muted outlook for sales in its current quarter. Shares of the chipmaker dropped 10%, to $44.52, in after-hours trading.
The Committee for Medicinal Products for Human Use of the European Medicines Agency issued a negative opinion on PTC Therapeutics' Translarna authorization following a re-examination procedure. Shares of the biopharmaceutical company declined 12%, to $23.50, in after-hours trading.
KLA posted a profit miss in its fiscal second quarter amid weaker demand for its products. Shares of the maker of equipment for the semiconductor industry fell 5.9%, to $603.75, in after-hours trading.
Write to Sabela Ojea at sabela.ojea@wsj.com
(END) Dow Jones Newswires
January 25, 2024 18:44 ET (23:44 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
Markets Brief: Stocks Are Starting to Look Cheap Again
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise
-
Microsoft Earnings: Firm Beats Forecasts on Strong AI and Cloud Demand
-
PG&E Earnings: Near-Term Regulatory Certainty Supports Industry-Leading Earnings Growth